Distant outcome of patients with locally advanced unresectable and metastatic esophageal cancer after multimodality treatment

Date 29 June 2016
Event ESMO World Congress on Gastrointestinal Cancer 2016
Session ESMO World Congress on Gastrointestinal Cancer 2016 - Abstracts book
Presenter I. Gruia
Citation Annals of Oncology (2016) 27 (2): 1-85. 10.1093/annonc/mdw199
Authors I. Gruia1, O. Trifanescu2, M. Bara3, V. Moldoveanu3, R. Anghel2, R. Toma3, L. Gales4, S. Constantinoiu5
  • 1Al. Trestioreanu Bucharest Institute of Oncology, Bucharest, Romania, /
  • 2UMF Carol Davila Bucharest, Al Trestioreanu Bucharest Institute of Oncology, Bucharest, Romania, /
  • 3Al Trestioreanu Bucharest Institute of Oncology, Bucharest, Romania, /
  • 4Bucharest Institute of Oncology, Bucharest, Romania, /
  • 5Sfanta Maria Clinical Hospital, Bucharest, Romania, /

Abstract

Esophageal cancer represents a major health problem around the world, being the sixth most common cause of cancer deaths. Combined modality therapy has been employed for the treatment of choice for locally advanced esophageal and esophageal gastric junction (EGJ) cancers all around the globe but a unanimous consensus is missing.